Efficacy of low-dose rituximab for mixed cryoglobulinemia

Clinical Immunology

Volumn 125, Issue 1, 2007, Pages 30-33

  Visentini, Marcella ^a   Granata, Massimo ^a   Veneziano, Maria Luisa ^a   Borghese, Federica ^a   Carlesimo, Maurizio ^a   Pimpinelli, Fulvia ^b   Fiorilli, Massimo ^a   Casato, Milvia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Cryoglobulinemia; Hepatitis C virus; Rituximab; Vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; INTERFERON; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CRYOGLOBULINEMIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MALE; PILOT STUDY; PRIORITY JOURNAL; REMISSION; SKIN NECROSIS; SKIN ULCER; TREATMENT RESPONSE; VASCULITIS; VIREMIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL PERFORATION; MALE; MIDDLE AGED; PILOT PROJECTS; SHOCK, SEPTIC; VIRAL LOAD;

EID: 34548511094     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.06.008     Document Type: Article

References (24)

1. Lamprecht P., Moosig F., Gause A., Herlyn K., Csernok E., Hansen H., and Gross W.L. Immunological and clinical follow-up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann. Rheum. Dis. 60 (2001) 385-390
2. Agnello V., Chung R.T., and Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 327 (1992) 1490-1495
3. Carbonari M., Caprini E., Tedesco T., Mazzetta F., Tocco V., Casato M., Russo G., and Fiorilli M. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J. Immunol. 174 (2005) 6532-6539
4. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P.L., Zilio P., Vernocchi A., Massazza M., Vendramin G., Tanzi E., and Zanetti A. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med. 330 (1994) 751-756
5. Casato M., Agnello V., Pucillo L.P., Knight G.B., Leoni M., Del Vecchio S., Mazzilli C., Antonelli G., and Bonomo L. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90 (1997) 3865-3873
6. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., and Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alfa with an anti-CD20. Blood 101 (2003) 3818-3826
7. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., Michelutti A., Baccarani M., Fanin R., and Ferraccioli G. Efficacy and safety of Rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
8. Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., Peters S.O., Gutzeit O., Arlt A.C., Solbach W., and Gross W.L. Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann. Rheum. Dis. 62 (2003) 1230-1233
9. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., Cavallo R., Alpa M., Costanzo P., Giachino O., Mazzucco G., and Sena L.M. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol. Dial. Transplant. 19 (2004) 3054-3061
10. Basse G., Ribes D., Kamar N., Mehrenberger M., Esposito L., Guitard J., Lavayssiere L., Oksman F., Durand D., and Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80 (2005) 1560-1564
11. Quartuccio L., Soardo G., Romano G., Zaja F., Scott C.A., De Marchi G., Fabris M., Ferraccioli G., and De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 45 (2006) 842-846
12. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
13. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., Van Vollenhoven R.F., Li N.F., Agarwal S., Hessey E.W., Shaw T.M., and DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 54 (2006) 1390-1400
14. Bianchettin G., Bonaccini C., Oliva R., Tramontano A., Cividini A., Casato M., Merlini G., Silini E., and Mondelli M.U. Analysis of hepatitis C virus hypervariable region 1 sequence in cryoglobulinaemic patients and associated controls. J. Virol. 81 (2007) 4564-4571
15. Kollmar O., Becker S., Schilling M.K., and Maurer C.A. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation 73 (2002) 669-670
16. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
17. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
18. Ramos-Casals M., Robles A., Brito-Zeron P., Nardi N., Nicolas J.M., Forns X., Plaza J., Yague J., Sanchez-Tapias J.M., and Font J. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin. Arthritis Rheum. 36 (2006) 189-196
19. Beckert S., Witte M., Wicke C., Konigsrainer A., and Coerper S. A new wound-based severity score for diabetic foot ulcers. A prospective analysis of 1,000 patients. Diabetes Care 29 (2006) 988-992
20. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54 (2006) 2377-2386
21. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin. Immunol. 117 (2005) 207-213
22. Lake-Bakaar G., Dustin L., McKeating J., Newton K., Freeman V., and Frost S.D. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109 (2007) 845-846
23. Aksoy S., Abali H., Kilickap S., Erman M., and Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin. Lab. Haematol. 28 (2006) 211-214
24. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., Roudaut A., Jamin C., Renaudineau Y., Roue I.Q., Cochener B., Youinou P., and Saraux A. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57 (2007) 310-317